Evidence for the Role of Peroxisome Proliferator-Activated Receptor-β/δ in the Development of Spinal Cord Injury

被引:42
|
作者
Paterniti, Irene [1 ]
Esposito, Emanuela [1 ,3 ]
Mazzon, Emanuela [1 ]
Galuppo, Maria [1 ]
Di Paola, Rosanna [3 ]
Bramanti, Placido [3 ]
Kapoor, Amar [2 ]
Thiemermann, Christoph [2 ]
Cuzzocrea, Salvatore [3 ]
机构
[1] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol Policlin Univ, I-98100 Messina, Italy
[2] St Bartholomews & Royal London Sch Med & Dent, Ctr Expt Med Nephrol & Crit Care, William Harvey Res Inst, London, England
[3] Ctr Neurolesi Bonino Pulejo, Inst Ricovero & Cura Carattere Sci, Messina, Italy
关键词
CYTOKINE PRODUCTION; IN-VIVO; MECHANISMS; APOPTOSIS; LIPOPOLYSACCHARIDE; DIFFERENTIATION; INFLAMMATION; EXPRESSION; LIGANDS; ATHEROSCLEROSIS;
D O I
10.1124/jpet.110.165605
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Several lines of evidence suggest a biological role for peroxisome proliferator-activated receptor (PPAR)-beta/delta in the pathogenesis many diseases. The aim of the present study was to evaluate the contribution of PPAR-beta/delta in the secondary damage in experimental spinal cord injury (SCI) in mice. To this purpose, we used 4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid (GW0742), a high-affinity PPAR-beta/delta agonist. Spinal cord trauma was induced by the application of vascular clips (force of 24 g) to the dura via a four-level T-5 to T-8 laminectomy. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, production of inflammatory mediators, tissue damage, and apoptosis. GW0742 treatment (0.3 mg kg(-1) i.p.) 1 and 6 h after the SCI significantly reduced 1) the degree of spinal cord inflammation and tissue injury (histological score), 2) neutrophil infiltration (myeloperoxidase activity), 3) nitrotyrosine formation, 4) proinflammatory cytokines expression, 5) nuclear factor-kappa B activation, 6) inducible nitric-oxide synthase expression, and 6) apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining, FasL, Bax, and Bcl-2 expression). Moreover, GW0742 significantly ameliorated the recovery of limb function (evaluated by motor recovery score). To elucidate whether the protective effects of GW0742 are related to activation of the PPAR-beta/delta receptor, we also investigated the effect of PPAR-beta/delta antagonist methyl-3-({[2-(methoxy)-4-phenyl]amino}sulfonyl)-2-thiophenecarboxylate (GSK0660) on the protective effects of GW0742. GSK0660 (1 mg/kg i.p. 30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect. Our results clearly demonstrate that GW0742 treatment reduces the development of inflammation and tissue injury associated with spinal cord trauma.
引用
收藏
页码:465 / 477
页数:13
相关论文
共 50 条
  • [31] Expression of peroxisome proliferator-activated receptor-γ1 and peroxisome proliferator-activated receptor-γ2 in visceral and subcutaneous adipose tissue of obese women
    Giusti, V
    Verdumo, C
    Suter, M
    Gaillard, RC
    Burckhardt, P
    Pralong, F
    DIABETES, 2003, 52 (07) : 1673 - 1676
  • [32] Role of peroxisome proliferator-activated receptor-α in acute pancreatitis induced by cerulein
    Genovese, Tiziana
    Mazzon, Emanuela
    Di Paola, Rosanna
    Muia, Carmelo
    Crisafulli, Concetta
    Malleo, Giuseppe
    Esposito, Emanuela
    Cuzzocrea, Salvatore
    IMMUNOLOGY, 2006, 118 (04) : 559 - 570
  • [33] Role of Peroxisome Proliferator-activated Receptor-α in Hepatobiliary Injury Induced by Ammonium Perfluorooctanoate in Mouse Liver
    Minata, Mutsuko
    Harada, Kouji H.
    Karrman, Anna
    Hitomi, Toshiaki
    Hirosawa, Michi
    Murata, Mariko
    Gonzalez, Frank J.
    Koizumi, Akio
    INDUSTRIAL HEALTH, 2010, 48 (01) : 96 - 107
  • [34] Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
    Lin Wang
    Yin Cai
    Liguo Jian
    Chi Wai Cheung
    Liangqing Zhang
    Zhengyuan Xia
    Cardiovascular Diabetology, 20
  • [35] Lipid metabolism:: peroxisome proliferator-activated receptor-α and atherosclerosis
    van Greevenbroek, MMJ
    van der Kallen, CJH
    CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (02) : 223 - 225
  • [36] The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
    Li, Jingjing
    Guo, Chuanyong
    Wu, Jianye
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2619 - 2628
  • [37] Regulation of peroxisome proliferator-activated receptor-γ in liver fibrosis
    Yang, Liu
    Chan, Che-Chang
    Kwon, Oh-Sang
    Liu, Songling
    McGhee, Jason
    Stimpson, Stephen A.
    Chen, Lihong Z.
    Harrington, W. Wallace
    Symonds, William T.
    Rockey, Don C.
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 291 (05): : G902 - G911
  • [38] Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling
    Adamson, DJA
    Frew, D
    Tatoud, R
    Wolf, CR
    Palmer, CNA
    MOLECULAR PHARMACOLOGY, 2002, 61 (01) : 7 - 12
  • [39] Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation
    Bishop-Bailey, David
    Bystrom, Jonas
    PHARMACOLOGY & THERAPEUTICS, 2009, 124 (02) : 141 - 150
  • [40] Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
    Wang, Lin
    Cai, Yin
    Jian, Liguo
    Cheung, Chi Wai
    Zhang, Liangqing
    Xia, Zhengyuan
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)